MSD Partners, China's Panacea raise $200m SPAC to target biotech, life sciences sectors

MSD Partners, China's Panacea raise $200m SPAC to target biotech, life sciences sectors

Wall Street, New York City, NY. Source: Martin Ceralde/Unsplash

Shanghai-based Panacea Venture has joined hands with Dell Technologies’ founder-backed investment advisor MSD Partners to sponsor a special purpose acquisition company (SPAC), which has raised $200 million through its listing in the US.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter